Senzime AB (publ) (SEZI) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to DNB Carnegie and this Q2 presentation with Sensime and its CEO Philip Sieber. My name is Claes Paulin and I will be hosting the Q&A session. First we will listen to a Q2 presentation and please go ahead Philip with the presentation. Okay, thank you Claes. Nice to be here on LINK. Let's start by a little bit of summary of the kind of the first six months of 2025. So good momentum, sales grew in local currencies with 90%, strong boost by our new next gen TetraGraph and the disposable sensors, the TetraSense. If we look at currency adjusted or the actual currency growth was 82% and we reached just under 50 million or 49.2 million SEK. Deliveries of sensors, which is the important KPI here for seeing recurring use, grew over 100%. The installed base of TetraGraphs is now over 4,100. Gross margin over the first six months has actually increased, and that's despite some hits we're going to take in Q2, or that we did take in Q2. I'll come back to it because of currencies and the U.S. tolls. Our operating... expenses remain stable, pretty much in line with last year, and that is despite significant investments in our commercial team and continued investments in innovation and R&D. So our EBITDA improved over the first six months with 23%, which is really driven by increased sales. If we look at some snapshots here, if we look at our rolling sales, we're continuing to be in this hockey stick phase. where one of the main triggers was in 23, when the US and European guidelines came out, which recommend using objective neuromuscular monitoring on all patients undergoing anesthesia and receiving paralytic drugs. And we're continuing to grow very nicely. And if you look at the curve to the right, this is the momentum of each quarter. We did have that dip in Q4...